Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPS vs LOKELMA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.
Treatment of hyperkalemia
Treatment of hyperkalemia,Off-label: Management of hyperkalemia in patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors
15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.
5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 m Eq/L; maximum 15 g three times daily (45 g/day).
Not applicable; SPS acts locally in the gastrointestinal tract and does not undergo systemic absorption. No terminal half-life can be defined.
Not applicable as LOKELMA is not systemically absorbed; terminal half-life is not measurable in traditional sense. Clinical effect duration correlates with gastrointestinal transit time (~6-8 hours for peak potassium lowering).
SPS is not absorbed systemically and is excreted unchanged in the feces.
Patiromer is not absorbed systemically and not metabolized; it is excreted unchanged in feces.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that is not absorbed systemically. It is excreted entirely in the feces, with no renal or biliary elimination. The resin-bound potassium is eliminated via the gastrointestinal tract.
Primarily eliminated unchanged in feces (approximately 90%) via gastrointestinal transit; <1% excreted in urine as absorbed sodium zirconium cyclosilicate is negligible.
Not applicable; SPS is not absorbed and does not bind to plasma proteins.
Not bound to plasma proteins as it is non-absorbed and acts locally in the gastrointestinal tract.
Not applicable; SPS remains within the gastrointestinal lumen and does not distribute into body tissues. Reported Vd is negligible.
Not applicable (locally acting, non-absorbed); apparent Vd is negligible due to lack of systemic absorption.
Oral: 0% (not absorbed); rectal: 0% (not absorbed). SPS acts locally without systemic availability.
Oral bioavailability is <1% as the drug is not absorbed from the gastrointestinal tract.
No specific dose adjustment is recommended based on GFR. Use with caution in patients with renal impairment due to risk of electrolyte disturbances (e.g., hypernatremia, hypokalemia).
No dose adjustment required based on GFR; monitor serum potassium more frequently in patients with e GFR <30 m L/min/1.73m² due to increased risk of hypokalemia.
No dose adjustment required for hepatic impairment. Monitor serum electrolytes and fluid balance in patients with hepatic disease.
No dose adjustment required for Child-Pugh Class A, B, or C; use with caution in severe hepatic impairment due to limited data.
Children (2-12 years): 0.5-2 g/kg/day divided every 4-6 hours; maximum 30 g/day. Administer orally or rectally as per adult guidance.
Safety and efficacy not established in pediatric patients; no approved dosing recommendations.
Use lowest effective dose; monitor electrolyte levels and renal function more frequently due to age-related decline in renal function and increased risk of electrolyte imbalance.
No specific dose adjustment; monitor serum potassium and renal function due to age-related decline in renal function and increased risk of hypokalemia.
No FDA black box warning.
None
Risk of intestinal necrosis, particularly with concomitant use of sorbitol,Electrolyte disturbances (e.g., hypokalemia, hypocalcemia, hypernatremia),Use with caution in patients with gastrointestinal disorders or postoperative patients
WARNING: Risk of hypomagnesemia; monitor serum magnesium. WARNING: Potential for gastrointestinal obstruction or perforation; use with caution in patients with severe gastrointestinal disorders. WARNING: May bind to other oral medications; separate dosing by at least 3 hours (or 6 hours for certain drugs).
Hypokalemia,Obstructive bowel disease,Neonates with reduced gut motility (postoperative or drug-induced),Concurrent use with sorbitol
Absolute: Hypersensitivity to patiromer or any excipient. Relative: Severe constipation, bowel obstruction, or impaction; postoperative gastrointestinal surgery.
Avoid high-potassium foods such as bananas, oranges, tomatoes, potatoes, and spinach to prevent excessive potassium intake. SPS may bind to some foods, but no specific food restrictions beyond potassium-rich foods are required. Do not mix SPS with fruit juices; use only water or simple syrup.
LOKELMA should be taken with food to reduce gastrointestinal side effects. No specific food restrictions, but high-potassium foods should be avoided as per dietary guidelines for hyperkalemia.
SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) from maternal use could indirectly affect the fetus. First trimester: No known teratogenic effects. Second/Third trimester: Risk of maternal electrolyte imbalance may impact fetal development. Use only if clearly needed.
No human studies. Animal reproduction studies not conducted. Insufficient data in pregnant women. Risk cannot be excluded. Due to mechanism (potassium binder, non-absorbed polymer), systemic absorption is minimal; fetal exposure unlikely. However, no controlled data. Use only if clearly needed and potential benefit justifies potential risk to fetus.
Excretion into breast milk is unlikely due to non-absorbable nature. M/P ratio not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal use is prolonged.
No data on presence in human milk, effects on breastfed infant, or on milk production. Given negligible oral absorption, excretion into breast milk is expected to be minimal. Caution advised; consider developmental and health benefits of breastfeeding alongside mother's clinical need.
No pharmacokinetic changes expected due to lack of absorption. Standard dosing may be used, but monitor electrolytes frequently due to altered renal function and volume of distribution in pregnancy. Dose adjustments are not required, but lower doses may suffice to avoid severe electrolyte shifts.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on current data. Use lowest effective dose to normalize potassium levels. Monitor potassium closely as pregnancy may alter electrolyte balance.
SPS (sodium polystyrene sulfonate) is a potassium-lowering resin that exchanges sodium for potassium in the GI tract. Administer orally or as a retention enema. Monitor for hypokalemia, hypomagnesemia, and sodium overload. Contraindicated in patients with bowel obstruction, severe constipation, or postoperative ileus due to risk of intestinal necrosis. Use with caution in patients on NSAIDs or with risk of colonic necrosis. Do not mix with sorbitol; use of sorbitol increases risk of intestinal necrosis. Monitor serum potassium levels frequently.
LOKELMA (patiromer) is a non-absorbed potassium-binding polymer indicated for hyperkalemia. Administer at least 6 hours apart from other oral medications due to potential binding. Monitor serum potassium weekly until stable. May cause hypomagnesemia; check magnesium levels periodically. Use with caution in patients with gastrointestinal motility disorders.
Take this medication exactly as prescribed, usually 1 to 4 times a day.,Do not mix SPS with orange juice or other fruit juices; it should be mixed with water or syrup.,This medication may cause constipation, so drink plenty of fluids and eat high-fiber foods.,If you experience severe constipation, severe abdominal pain, vomiting, or blood in vomit or stool, seek medical attention immediately.,Avoid taking other medications within 3 hours of SPS as it may bind to them and reduce their effectiveness.,Inform your doctor if you have a history of bowel obstruction, constipation, or kidney disease.,Do not use sorbitol or other laxatives with SPS unless directed by your doctor.
Take LOKELMA exactly as prescribed, usually once daily with food.,Separate LOKELMA from other oral medications by at least 6 hours.,Do not crush, chew, or open capsules; swallow whole.,Notify your doctor if you experience constipation, nausea, or stomach pain.,Do not stop taking LOKELMA without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPS vs LOKELMA, answered by our medical review team.
SPS is a Potassium Binder that works by SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.. LOKELMA is a Potassium Binder that works by Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPS and LOKELMA depend on the specific clinical indication. These are both Potassium Binder agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPS is: 15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.. The standard adult dose of LOKELMA is: 5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 m Eq/L; maximum 15 g three times daily (45 g/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPS and LOKELMA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPS is classified as Category C. SPS (sodium polystyrene sulfonate) is not absorbed systemically; therefore, no direct fetal risk is expected. However, electrolyte disturbances (e.g., hypokalemia, hypocalcemia) fr. LOKELMA is classified as Category C. No human studies. Animal reproduction studies not conducted. Insufficient data in pregnant women. Risk cannot be excluded. Due to mechanism (potassium binder, non-absorbed polymer). Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.